ReviewFrontiers in cell and developmental biology2022
Cyclodextrin nanoparticles for diagnosis and potential cancer therapy: A systematic review.
Review in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- From Inclusion Complexes to Metabolic Signaling: The Emerging Role of γ-Cyclodextrin in Gut Microbiota and Metabolic Regulation.Molecules (Basel, Switzerland) · 2026Review
- Peganum harmala leaf extract mediated green synthesised polyvinyl alcohol zinc oxide beta cyclodextrin nanocomposite for anticancer and antimicrobial applications.Discover nano · 2026Article
- Breaking barriers: nanosystems to overcome solubility and permeability challenges of second-generation tyrosine kinase inhibitors.Beilstein journal of nanotechnology · 2026Review
- Formulation Strategies for Immunomodulatory Natural Products in 3D Tumor Spheroids and Organoids: Current Challenges and Emerging Solutions.Pharmaceutics · 2025Review
- The Potential of Amphiphilic Cyclodextrins as Carriers for Therapeutic Purposes: A Short Overview.Pharmaceutics · 2025Review
- A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer.Breast cancer research : BCR · 2025Article
- Cyclodextrins and their potential applications for delivering vitamins, iron, and iodine for improving micronutrient status.Drug delivery and translational research · 2025Review
- Innovative nanocarrier systems for enhanced delivery of phyto-active compounds in cancer therapy.Nanomedicine (London, England) · 2025Review
- Exploring the potential of polymers: advancements in oral nanocarrier technology.Beilstein journal of nanotechnology · 2025Review
- Cyclodextrins: Advances in Chemistry, Toxicology, and Multifaceted Applications.Molecules (Basel, Switzerland) · 2024Review
- The synergistic effect of metal ions and amino acids on the fermentation of β-CGTase-producing statin DF257.3 Biotech · 2024Article
- Exploring the Potential of Nanogels: From Drug Carriers to Radiopharmaceutical Agents.Advanced healthcare materials · 2024Review
- A Systematic Review of Nanomedicine in Glioblastoma Treatment: Clinical Efficacy, Safety, and Future Directions.Brain sciences · 2023Review
- Synthetic Receptors for Early Detection and Treatment of Cancer.Biosensors · 2023Review
- Surface engineered mesoporous silica carriers for the controlled delivery of anticancer drug 5-fluorouracil: Computational approach for the drug-carrier interactions using density functional theory.Frontiers in pharmacology · 2023Article
- Liquid metal nanoparticles for enhanced delivery of benzoporphyrin derivative in photodynamic cancer therapy.Photochemistry and photobiologyArticle
- Recent advances in tumor targeted polymeric nanoparticles for HNC treatment: Enhancing therapeutic efficacy via engineered and biocompatible drug delivery systems.Journal of oral biology and craniofacial researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is still one of the world's deadliest health concerns. As per latest statistics, lung, breast, liver, prostate, and cervical cancers are reported topmost worldwide. Although chemotherapy is most widely used methodology to treat cancer, poor pharmacokinetic parameters of anticancer drugs render them less effective. Novel nano-drug delivery systems have the caliber to improve the solubility and biocompatibility of various such chemical compounds. In this regard, cyclodextrins (CD), a group of natural nano-oligosaccharide possessing unique physicochemical characteristics has been highly exploited for drug delivery and other pharmaceutical purposes. Their cup-like structure and amphiphilic nature allows better accumulation of drugs, improved solubility, and stability, whereas CDs supramolecular chemical compatibility renders it to be highly receptive to various kinds of functionalization. Therefore combining physical, chemical, and bio-engineering approaches at nanoscale to specifically target the tumor cells can help in maximizing the tumor damage without harming non-malignant cells. Numerous combinations of CD nanocomposites were developed over the years, which employed photodynamic, photothermal therapy, chemotherapy, and hyperthermia methods, particularly targeting cancer cells. In this review, we discuss the vivid roles of cyclodextrin nanocomposites developed for the treatment and theranostics of most important cancers to highlight its clinical significance and potential as a medical tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.